Zhimin Du

This inventor holds 25 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 13 EPO patents, primarily in Cancer Therapeutics. Top assignee: Gilead Sciences, Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhimin Du. Retrieved from https://idiyas.com/inventor/zhimin-du

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 10)

% Patents Active = 92.0

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 13 (Patent Applications = 19)

Average Co-Inventor Count = 11.9

ph-index = 4

Forward Citations = 57(Granted Patents)

Location History:

Foster City, CA (US) (2011)
Belmont, CA (US) (2016 - 2024)

Company Filing History:

25 out of 946

Gilead Sciences, Inc.

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

PD-1/PD-L1 Inhibitors

LPA Receptor Antagonists

IKAROS Zinc Finger Family

Therapeutic Compounds

Triazole Carbamate

Phosphatidylinositol 3-Kinase

Tank-Binding Kinase

Syk Inhibitors

Antiviral Compounds

Pyrrolidines

Cancer Treatment

HIV Virus Infection

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12590062 - PD-1/PD-L1 inhibitors (2026-03-31),

2. 12503454 - LPA receptor antagonists and uses thereof (2025-12-23),

3. 12358887 - IKAROS Zinc Finger Family degraders and uses thereof (2025-07-15),

4. 12338233 - PD-1/Pd-L1 inhibitors (2025-06-24),

5. 12122764 - IKAROS zinc finger family degraders and uses thereof (2024-10-22),

6. 12084467 - Therapeutic compounds for HIV virus infection (2024-09-10),

7. 11999717 - Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof (2024-06-04),

8. 11897862 - IKAROS zinc finger family degraders and uses thereof (2024-02-13),

9. 11584738 - LPA receptor antagonists and uses thereof (2023-02-21),

10. 11555029 - PD-1/PD-L1 inhibitors (2023-01-17),

11. 11548871 - Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof (2023-01-10),

12. 11236085 - PD-1/PD-L1 inhibitors (2022-02-01),

13. 11021467 - Phosphatidylinositol 3-kinase inhibitors (2021-06-01),

14. 10899735 - PD-1/PD-L1 inhibitors (2021-01-26),

15. 10710986 - PD-1/PD-L1 inhibitors (2020-07-14),

Title: Innovator Spotlight - Zhimin Du: Pioneering Solutions in Biomedical Research

Introduction:

Zhimin Du, a distinguished innovator based in Belmont, CA, has made significant contributions to the field of biomedical research. With a portfolio boasting 18 patents, Zhimin Du has established himself as a leading figure in the domain of molecular therapeutics.

Latest Patents:

Among his recent patents, Zhimin Du has introduced groundbreaking innovations such as the 'IKAROS zinc finger family degraders and uses thereof' and 'LPA receptor antagonists and uses thereof.' These patents focus on developing compounds that target specific proteins to treat diseases like cancer, fibrosis, and liver conditions.

Career Highlights:

Zhimin Du is a vital asset to Gilead Sciences, Inc., a prominent organization in the biopharmaceutical sector. His role at Gilead Sciences, Inc. involves spearheading research initiatives aimed at advancing novel drug therapies and treatment modalities for various ailments.

Collaborations:

Within the dynamic environment of Gilead Sciences, Inc., Zhimin Du collaborates closely with accomplished peers such as Barton W. Phillips and William John Watkins. Together, they form a formidable team dedicated to pushing the boundaries of biomedical innovation.

Conclusion:

In conclusion, Zhimin Du's relentless pursuit of scientific excellence and his knack for transformative discoveries underscore his status as a visionary inventor. His pioneering work not only reflects his ingenuity but also his commitment to enhancing healthcare solutions. Zhimin Du stands as a testament to the enduring impact of innovation in shaping the future of medicine.

Profile summary based on public USPTO records.